A Concerning Trend for Patients With Pulmonary Hypertension in the Era of Evidence-Based Medicine

Circulation. 2019 Apr 16;139(16):1861-1864. doi: 10.1161/CIRCULATIONAHA.118.037613.

Authors

Bradley A Maron^{1

2}, John J Ryan³

Affiliations

¹ Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (B.A.M.).
² Department of Cardiology, Boston VA Healthcare System, MA (B.A.M.).
³ Division of Cardiovascular Medicine, Department of Medicine, University of Utah, Salt Lake City (J.J.R.).

PMID: 30986105
DOI: 10.1161/CIRCULATIONAHA.118.037613

No abstract available

Keywords: World Health Organization; endothelin receptor antagonists; heart failure; hypertension, pulmonary; phosphodiesterase 5 inhibitors.

MeSH terms

Antihypertensive Agents / therapeutic use*
Clinical Trials as Topic
Endothelin Receptor Antagonists / therapeutic use*
Evidence-Based Medicine
Humans
Hypertension, Pulmonary / drug therapy*
Sildenafil Citrate / therapeutic use*
Vascular Remodeling

Substances

Antihypertensive Agents
Endothelin Receptor Antagonists
Sildenafil Citrate